Poxel SA(FR:POXEL)
€0.15-0.01 (-3.33%)
FR:POXEL
Poxel SA stock drug pipeline
€0.15
At close:-0.01 (-3.33%)
Want to see FR:POXEL full AI Analyst Report?
Poxel SA (POXEL) Drug Pipeline
8 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Pxl770 | Nash - Nonalcoholic Steatohepatitis | Phase I | Completed | Study to Assess the Safety, Tolerability, and Pharmacokinetics of PXL770 in Healthy Subjects. | Jun 22, 2022 | ― |
| Pxl065 | Ald (Adrenoleukodystrophy) | Phase II | Withdrawn | Study to Assess PXL065 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD) | Jan 06, 2022 | ― |
| Pxl770 | Adrenomyeloneuropathy | Phase II | Withdrawn | Study to Assess PXL770 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD) | Nov 16, 2021 | ― |
| Pxl065 | Nash - Nonalcoholic Steatohepatitis | Phase II | Completed | Study of PXL065 in Patients With Nonalcoholic Steatohepatitis (NASH) | Mar 23, 2020 | ― |
| Pxl770 | Nonalcoholic Fatty Liver | Phase I | Completed | A Study to Assess the Pharmacokinetics of PXL770 After 4 Weeks of Treatment in Subjects With NAFLD | May 13, 2019 | ― |
| 14C Labeled Pxl770 | Healthy | Phase I | Completed | Pharmacokinetics and Metabolism of (14C)-Labelled PXL770 | Mar 20, 2019 | ― |
| Imeglimin | Hepatic Impairment | Phase I | Completed | Pharmacokinetics of Imeglimin in Hepatic Impaired Subjects | Jan 10, 2019 | ― |
| Pxl770 | Nonalcoholic Fatty Liver | Phase II | Completed | A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD | Nov 28, 2018 | ― |
| Imeglimin, Imeglimin Reference Product | Bioequivalence | Phase I | Completed | Bioequivalence of Imeglimin Tablet Formulations | Aug 23, 2018 | ― |
| Cimetidine, Imeglimin | Healthy | Phase I | Completed | Effect of Cimetidine on the PK of Imeglimin | Jun 08, 2018 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Pxl770 | Phase I | Nash - Nonalcoholic Steatohepatitis | Completed | Study to Assess the Safety, Tolerability, and Pharmacokinetics of PXL770 in Healthy Subjects. | Jun 22, 2022 | ― |
| Pxl065 | Phase II | Ald (Adrenoleukodystrophy) | Withdrawn | Study to Assess PXL065 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD) | Jan 06, 2022 | ― |
| Pxl770 | Phase II | Adrenomyeloneuropathy | Withdrawn | Study to Assess PXL770 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD) | Nov 16, 2021 | ― |
| Pxl065 | Phase II | Nash - Nonalcoholic Steatohepatitis | Completed | Study of PXL065 in Patients With Nonalcoholic Steatohepatitis (NASH) | Mar 23, 2020 | ― |
| Pxl770 | Phase I | Nonalcoholic Fatty Liver | Completed | A Study to Assess the Pharmacokinetics of PXL770 After 4 Weeks of Treatment in Subjects With NAFLD | May 13, 2019 | ― |
| 14C Labeled Pxl770 | Phase I | Healthy | Completed | Pharmacokinetics and Metabolism of (14C)-Labelled PXL770 | Mar 20, 2019 | ― |
| Imeglimin | Phase I | Hepatic Impairment | Completed | Pharmacokinetics of Imeglimin in Hepatic Impaired Subjects | Jan 10, 2019 | ― |
| Pxl770 | Phase II | Nonalcoholic Fatty Liver | Completed | A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD | Nov 28, 2018 | ― |
| Imeglimin, Imeglimin Reference Product | Phase I | Bioequivalence | Completed | Bioequivalence of Imeglimin Tablet Formulations | Aug 23, 2018 | ― |
| Cimetidine, Imeglimin | Phase I | Healthy | Completed | Effect of Cimetidine on the PK of Imeglimin | Jun 08, 2018 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Poxel SA (FR:POXEL) have in its pipeline
Poxel SA FR:POXEL is currently developing the following drugs: Pxl770, Pxl065, 14C Labeled Pxl770, Imeglimin, Imeglimin, Imeglimin Reference Product, Cimetidine, Imeglimin, Rosuvastatin, Pxl770, Moxifloxacin, Imeglimin. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

